← Back to search

Genexine, Inc.

GNXCF · US OTC

Biotechnology

Genexine, Inc. engages in research and development of therapeutic vaccines hybrid Fc fusion proteins (hyFc) and DNA (deoxyribonucleic acid) therapeutic vaccines. It operates through the following business divisions: Novel drug development and Cell culture media manufacturing. The company was founded by Young Chul Sung on June 8, 1999 and is headquartered in Seongnam-si, South Korea.

ESG Scores

Overall ESG
2.1
Environmental
6.0
Social
3.9
Governance
3.0

Gender Diversity

Female Directors0.1429%
Women in Workforce0.608%
CEO GenderMale